27.07.2011 • News

Praxair Q2 Profit Rises

Praxair Wednesday said net income in the second quarter increased to $425 million or $1.38 per share from $371 million or $1.19 per share in the prior year.

On average, 16 analysts polled by Thomson Reuters expected the company to earn $1.37 per share in the quarter. Analysts' estimates typically exclude special items.

Sales increased 13% to $2.86 billion from $2.53 billion, surpassing Wall Street view of $2.79 billion.

For the third quarter, Praxair expects earnings per share in the range of $1.35 to $1.40. Analysts expect earnings of $1.39 per share for the quarter.
Further, the company increased its full year earnings guidance to $5.40 to $5.50 per share from the prior range of $5.35 to $5.45.

For 2011, Praxair expects sales in the area of $11.2 billion. The previous projection was for sales in the area of $11 billion.

Wall Street expects 2011 earnings of $5.47 per share on revenues of $11.16 billion.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read